RAPT Stock Summary and Trading Ideas (Rapt Therapeutics | NASDAQ:RAPT)

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Rapt Therapeutics trades on the NASDAQ stock market under the symbol RAPT.

As of December 11, 2024, RAPT stock price was flat at $1.09 with 133,021 million shares trading.

RAPT has a beta of 2.13, meaning it tends to be more sensitive to market movements. RAPT has a correlation of 0.02 to the broad based SPY ETF.

RAPT has a market cap of $38.10 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, RAPT traded as high as $40.74 and as low as $.92.

The top ETF exchange traded funds that RAPT belongs to (by Net Assets): VTI, VXF, IWM, IWN, VTWO.

RAPT has underperformed the market in the last year with a price return of -93.8% while the SPY ETF gained +33.5%. RAPT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -45.2% and -2.7%, respectively, while the SPY returned +11.0% and +1.1%, respectively.

RAPT support price is $.99 and resistance is $1.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RAPT shares will trade within this expected range on the day.